Run for recovery and sleep
GH Pulse (Ipamorelin + CJC-1295 no-DAC)
beginner12 weeksThe standard growth hormone secretagogue pairing: a GHRH analogue (CJC-1295 without DAC, also sold as Mod GRF 1-29) plus a ghrelin receptor agonist (ipamorelin), injected together so the two mechanisms produce a larger pulse than either alone. Both are short-acting, which is the point - it mimics a natural pulse instead of flattening it.
Also sold as Ipa/CJC, Mod GRF + Ipamorelin, GHRP + GHRH.
Cautions — 8 on record
Read before running any of this
- Neither compound is an approved medicine. Ipamorelin development was discontinued; CJC-1295 was never approved.
- Do not run with an active malignancy. Raising GH and IGF-1 in the presence of a tumor is the single clearest reason not to touch this class.
- Not for use in pregnancy, and not for under-18s - the growth plates are still open.
- Water retention, morning puffiness and hand tingling are common and are the signal to reduce the dose. Persistent numbness can mean carpal tunnel pressure.
- Both are banned by WADA.
- The empty-stomach requirement is real. Dosed after a meal you are largely wasting the injection.
- Get a baseline IGF-1 and recheck it. This class is where people quietly push into a range they did not intend.
- Cycle it. Run a defined block and take time off rather than dosing indefinitely.
Components
What is in it, and when
| Compound | Dose | Frequency | Time | Notes | |
|---|---|---|---|---|---|
| CJC-1295 without DAC (Mod GRF 1-29) | 100 mcg100 mcg–100 mcg | Once daily7×/week | Pre-bed | The no-DAC version is deliberate. The DAC version has a week-long half-life and gives a continuous bleed rather than a pulse. 100 mcg is the usual saturation dose - more does not produce a bigger pulse. Draw into the same syringe as the ipamorelin. | Calculator → |
| Ipamorelin | 200 mcg100 mcg–300 mcg | Once daily7×/week | Pre-bed | Chosen over hexarelin or GHRP-6 because it barely touches cortisol or prolactin. Dose on an empty stomach - at least 2 hours after eating and no food for about 30 minutes after - since circulating glucose and fatty acids blunt the pulse. | Calculator → |
Doses are per administration, in the canonical unit. The second line under each dose is the range people run. Each calculator link prefills the reconstitution math for that component.
Delivered dose vs standalone dose
How these doses compare to running each compound alone
Each bar is that compound’s own dose range from its monograph, with a marker where this protocol puts it. A marker outside the band means the protocol is not dosing that compound the way it is dosed on its own — for a fixed-ratio vial that is arithmetic, not a choice.
CJC-1295 without DAC (Mod GRF 1-29)
At the floor of the range- Per dose
- 100% of typical
- Per week
- 700 mcg · 100% of standalone
- Cycle total
- 8.4 mg · 84 doses
The no-DAC version is deliberate. The DAC version has a week-long half-life and gives a continuous bleed rather than a pulse. 100 mcg is the usual saturation dose - more does not produce a bigger pulse. Draw into the same syringe as the ipamorelin.
Ipamorelin
Within standalone range- Per dose
- 100% of typical
- Per week
- 1.4 mg · 100% of standalone
- Cycle total
- 16.8 mg · 84 doses
Chosen over hexarelin or GHRP-6 because it barely touches cortisol or prolactin. Dose on an empty stomach - at least 2 hours after eating and no food for about 30 minutes after - since circulating glucose and fatty acids blunt the pulse.
Schedule — 12 weeks
Week by week
| Compound | 1Week 1 | 2Week 2 | 3Week 3 | 4Week 4 | 5Week 5 | 6Week 6 | 7Week 7 | 8Week 8 | 9Week 9 | 10Week 10 | 11Week 11 | 12Week 12 | Cycle total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CJC-1295 without DAC (Mod GRF 1-29)100 mcg · 7×/wk | 8.4 mg84 doses | ||||||||||||
| Ipamorelin200 mcg · 7×/wk | 16.8 mg84 doses |
The dataset records one dose per component, so every dosing week is identical. Where a protocol note describes a loading phase followed by maintenance, that phase change is in the note, not in the schedule — read the component notes before assuming the grid is the whole story.
Evidence
What is actually known
The mechanism is well established - a GHRH analogue and a ghrelin receptor agonist together produce a synergistic GH pulse in published human work. What is not established is that this translates into meaningful body-composition or recovery outcomes in healthy adults, which has not been tested. Doses come from community practice, not a label.
SourcesPubMedClinicalTrials.gov
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.